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Background: The benefit of pre and post-operative administration of non-steroidal anti-inflammatory drugs for the
relief of post-operative pain and control of inflammation in horses following orthopaedic surgery has not been
previously investigated in controlled clinical field trials, and the utility of such treatment is a matter of ongoing
dispute. Recently the utility of post-operative pain management was emphasized. It was therefore our aim to
determine the efficacy of meloxicam in horses following partial resection of fractured splint bones. This condition
was selected since the limited extent of the insult and the defined surgical intervention allowed the conduct of a
randomized, double blinded, placebo-controlled, parallel group, multi-centre clinical field study in a homogenous
patient population.
Results: Sixty-six client owned horses requiring unilateral partial splint bone resection were recruited in 15 centres
in Germany and were allocated in a 1:1 ratio to receive meloxicam, 0.6 mg/kg for 5 days.
Lameness at trot grades prior to surgery were similar in the meloxicam and placebo treatment groups but were
significantly lower in the meloxicam group on day 6 post surgery. Clinical scores for soft tissue swelling and
assessment of analgesic and anti-inflammatory efficacy by the investigators at the end of the study were
significantly better for the meloxicam compared to the placebo group. No treatment-related adverse reactions
were observed.
Conclusion: The administration of meloxicam i.v. once prior to surgery followed by once daily oral administration
for four consecutive days is efficacious for the control of post-operative pain and inflammation in horses
undergoing orthopaedic surgery.
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Splint bone fracture, Partial resection, Lameness at trotBackground
Surgical intervention on distal extremities in horses is a
standard of care for many orthopaedic conditions in-
cluding splint bone fractures, condylar fractures, arthro-
scopic joint revisions, and various other conditions [1-3].
While orthopaedic surgical procedures are well estab-
lished, the medical management of pain and inflamma-
tion resulting from such intervention remains to be an* Correspondence: chris.rundfeldt@t-online.de
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unless otherwise stated.under-addressed field. The benefit of pain management
during and after orthopaedic surgery is a matter of con-
troversial discussion. In the past it has been suggested
that analgesics be withheld in equine patients to main-
tain protective reflexes and reduce the risk of injury [4],
but more recently the utility of post-operative pain man-
agement was emphasized [4-6].
Nonsteroidal anti-inflammatory drugs (NSAIDs) are ex-
tensively used as analgesics in veterinary medicine, having
proven efficacy in dogs and cats for post-operative pain
management in orthopaedic surgery [7]. NSAIDs combinel. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Walliser et al. BMC Veterinary Research  (2015) 11:113 Page 2 of 8analgesia with anti-inflammatory activity. This pharma-
cology is the result of their inhibition of the cyclooxy-
genase pathway and prevention of the formation of
pro-inflammatory prostaglandins at the site of injury
[8]. Despite recommendations for the use of NSAIDs in
equine orthopaedic surgery [5,9,10], evidence for effi-
cacy from controlled clinical field studies is limited
[4,11]. Meloxicam is an NSAID which is licensed and
widely used for the treatment of pre- and post-operative
pain and inflammation following orthopaedic and soft
tissue surgery in cats and dogs [12]. It is licensed for use
in horses for the alleviation of inflammation and relief
of pain in both acute and chronic musculo-skeletal dis-
orders as well as for the relief of pain associated with
colic [13]. The anti-inflammatory efficacy of meloxicam
in equines has been demonstrated in pharmacodynamic
and pharmacokinetic studies [14,15]. But to date no data
are available supporting its use in post-operative pain
control in orthopaedic surgery.
The objective of this study was to examine the effi-
cacy of meloxicam for the control of post-operative
pain and inflammation in horses undergoing ortho-
paedic surgery in a double-blind placebo-controlled
study. Partial resection of fractured splint bones is a
small, well defined surgical intervention. This condition
was therefore selected as a condition to demonstrate
clinical efficacy of meloxicam. Both, the limited extent
of pre-surgical pain and the limited and standardized
surgical intervention, which involves only non-weight
bearing structures and which likely does not result in
severe pain, enables a placebo controlled study ap-
proach. Part of the data have been previously published
in abstract form [16].Methods
The study was designed as a randomized, double blind,
placebo-controlled parallel group multi-centre clinical
field study using two treatment groups with equal num-
bers of clinical cases per group and was conducted in
compliance with good clinical practice [17]. The use of
a placebo in the clinical field trial setting of the present
study can be justified by the low level of post-operative
pain induced by the limited surgical intervention, non-
availability of a licensed veterinary medicine for peri-
operative treatment, or at least a drug with proven
clinical evidence for efficacy, as comparator for the
clinical indication investigated. The study was approved
by the local competent authority of the principle inves-
tigator Dr. Walliser, Regierungspräsidium Karlsruhe,
Baden-Würtemberg, Az. 35–9182.00, and by all local
authorities of all participating study centres in full compli-
ance with German drug law, and by the local animal wel-
fare officer of Boehringer Ingelheim Vetmedica GmbH.Animals
Client owned horses requiring orthopaedic surgery for a
closed splint bone fracture associated with marked exo-
stosis and development of connective tissue indurations
were eligible for inclusion in the study with the consent
of the owner. Exclusion criteria were defined as pregnant
mares, foals less than 6 weeks of age, horses with distal
fractures of the splint bones with absolutely non-reactive
tissue, compound fractures, proximal fractures which re-
quired internal fixation, lameness of other origin (e.g.
coffin joint, fetlock joint), or clinical chemistry values in-
dicative of hepatic, renal or hemorrhagic disease. Prior
treatment with short acting corticosteroids or NSAIDs
during the previous 8 days or treatment with long acting
corticosteroids during the previous 8 weeks also pre-
cluded inclusion in the study.
Treatments
Premedication for surgery was performed according to the
study site’s usual practices (except for any treatment that
might have affected or masked the clinical symptoms of
post-operative pain (e.g. NSAIDs and corticosteroids). For
pain control during surgery only drugs with duration of
action of up to 4 hours were permitted. In most cases
L-methadone and/or ketamine were administered; the
use of these analgesic agents did not differ between the
two treatment groups. Induction and maintenance of in-
halation anaesthesia was also performed according to
the study site’s usual practices. To control for potential
exaggerated pain after surgery during the study conduct,
butorphanol was allowed as a rescue medication for the
control of very strong pain but was not required or used
in any case.
After an initial examination and confirmation of eligibil-
ity for inclusion in the study, the horses were allocated
according to a randomization list to one of two treatments
as follows: (i) a single intravenous injection of meloxicama
(0.6 mg/kg b.w.) immediately prior to premedication
followed by (starting on the following morning) 4 once
daily oral administrations of meloxicamb at the same dos-
age; or (ii) a single intravenous injection of placebo imme-
diately prior to premedication followed (starting on the
following morning) by 4 once daily equivalent volume oral
administrations of placebo. The parenteral and oral investi-
gational interventions for the two treatment groups looked
identical and were identically packaged and labelled. The
formulation of the placebo was identical to that of the ac-
tive treatment except for the absence of the active ingredi-
ent. The administration of the interventions was carried
out by the blinded investigator at each study site.
Clinical examinations
General characteristics (e.g. age, breed, and bodyweight),
blood chemistry profile, affected limb, site and date of
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surgery were recorded, and diagnosis was confirmed by
radiographic assessment before surgery. Daily monitor-
ing included body temperature (°C), heart rate (beats/
minute), respiratory rate (breaths/minute) and food in-
take (scoring system: 0, unchanged (normal); 1, reduced
by ≤ 1/3; 2, by ≥ 1/3; 3, none). Immediate post-surgery
recovery was assessed in terms of the number of attempts
which the horses made to stand until they actually man-
aged to remain standing upright and the interval between
the time of extubation and the time when the horse was
able to remain standing upright.
The primary endpoint was prospectively defined as
lameness at trot (LAMET) (prior to and at 3 and 6 days
after surgery) according to the severity of lameness grad-
ing system of the American Association of Equine Prac-
titioners (AAEP) [18]. LAMET was not assessed on day
1 post surgery due to the proximity to the surgery. To
evaluate the level of pain perception at rest throughout
the study, lameness at walk (LAMEW) was assessed
prior to and at 1, 3 and 6 days after surgery. Assessment
of soft tissue swelling, wound healing and analgesic and
anti-inflammatory efficacy were additional secondary
endpoints. At the surgical site, soft tissue swelling was
evaluated on Days 1, 3 and 6, and local palpatory pain
on Days 3 and 6, using a 4 point scoring system for both
endpoints with 0, 1, 2, 3 indicating none, mild, moderate
and severe, respectively. The circumference (cm) of the
affected area and wound healing at the surgical site were
evaluated on Days 3 and 6; wound healing was scored as
either: 0, no signs of complications; 1, increased local
temperature; 2, wound secretion; 3, suture dehiscence
and 4, other complications such as wound infections.
Dressings were changed on Days 3 and 6. At the end of
the study the investigator provided a general assessment
of analgesic and anti-inflammatory efficacy of the treat-
ment for each horse using a 4 point grading system
whereby 1, 2, 3 and 4 denoted excellent, good, moderate
and poor, respectively.
Data analyses
Baseline characteristics for the horses in the study were
summarized using descriptive statistics. Data for LAMET
and LAMEW were analysed using ordinal logistic regres-
sion (OLR) analysis [19] with treatment as the main effect,
first with all six AAEP categories and then for LAMET
also with a reduced lameness scale, which was constructed
post-hoc to focus on clinically relevant lameness at trot
(CRLAT): 1, none or minimal (i.e. combination of AAEP
grades 0 and 1); 2, mild (i.e. AAEP grade 2); and 3, moder-
ate to severe (i.e. combination of AAEP grades 3, 4 and 5).
To adjust for potential differences in severity of lameness
prior to treatment (Day 0), the LAMET and CRLAT data
on both study days 3 and 6 were also evaluated using theOLR analysis with adjustment for the respective values at
Day 0. For this purpose, the OLR model included two cat-
egorical variables, treatment (Meloxicam or placebo) as
the main effect and LAMET or CRLAT, respectively, at
Day 0 as a potential confounder [19,20].
Data on the categorical secondary efficacy variables
(assessments of soft tissue swelling and local palpatory
pain at the surgery site, wound healing and the general
assessment of analgesic and anti-inflammatory efficacy)
were evaluated statistically via chi-square analyses. Data
on the quantitative traits, i.e. circumference of the most
severely affected area, rectal temperature, heart rate, and
respiratory rate, were evaluated using repeated-measures
analysis of variance or covariance with treatment and day
as fixed effects and, for each of the three physiological var-
iables, with the corresponding values at Day 0 as a covari-
ate. The analysis of each of these four variables included
Tukey-Kramer mean comparisons between the meloxi-
cam and placebo treatment groups both overall and on
each study day. All statistical analyses were carried out
using the SAS computer software package [20].
Results
A total of 15 investigators contributed 66 clinical cases
in the study. Six of the cases enrolled (two in meloxicam
and four in placebo group) were subsequently found to
be in violation of the inclusion/exclusion criteria and
were not further considered in the evaluation of the re-
sults for efficacy. Two cases on placebo had two fractures;
one horse on placebo got a 2nd fracture on the day after
surgery preventing adequate evaluation of lameness com-
pared to pre-surgery; in three horses (one in the placebo
group and two in the meloxicam group), the required pre-
study procedures were not performed according to proto-
col or were not documented correctly, preventing the
evaluation of treatment efficacy for these cases. All 6 were
excluded from the primary study population.
Population characteristics of the meloxicam and placebo
groups were well balanced. In particular, more than 80 %
of the horses in both treatment groups were Warmbloods,
and the two treatment groups were well balanced with re-
spect to sex, age, bodyweight and duration of lameness
prior to surgery (Table 1). The treatment groups were
broadly similar with regard to the radiographic assessment
of the affected splint bone prior to surgery and with regard
to both the location of the fracture and the severity of
callus formation. Fractures were most frequently pre-
sented in one of the forelimbs in both treatment groups
and represented 54.8 and 69.0 % of the cases in the melox-
icam and placebo groups, respectively. The distribution of
fractures between left and right limbs was equal for the
two groups. Mild to moderate callus formation was ob-
served in 96.8 and 93.1 % of the cases in the meloxicam
and placebo groups, respectively.











[kg, mean ± SD]
Lameness duration
[days, mean ± SD]
Meloxicam 31 83.3 / 13.3 / 3.3 60 / 4 / 36 9.5 ± 4.9 537 ± 96 23.2 ± 18.4
Placebo 29 86.2 / 3.5 / 10.4 52.2 / 13 / 34.8 10.2 ± 3.7 539 ± 107 25.0 ± 24.8
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prior to surgery and again on Day 3 and Day 6; the dis-
tribution of LAMET scores are summarised in Table 2.
As determined by OLR, the lameness scores on Day 6
were significantly lower in the meloxicam group as com-
pared to the placebo group (p = 0.007), indicating a sig-
nificant clinical effect of meloxicam treatment. A similar
trend towards a positive treatment effect, although not
statistically significant (p = 0.067), was seen on Day 3.
However, more cases with no or minimal lameness were
included in the meloxicam group; 38.8 % of horses in
the meloxicam group had either no or only minimal lame-
ness at trot on Day 0 compared to 20.6 % for the placebo
group (Table 1). The frequency of horses with moderate
lameness (grade 3) was comparable in both groups (48.4 %
and 55.2 %). While the difference in LAMET on Day 0
was not statistically significant (p = 0.162), a baseline ad-
justment in the evaluation of the treatment success was
deemed appropriate to correct for a potential advantageTable 2 Distribution of study horses by the AAEP grade for
lameness at trot (LAMET) on study days 0, 3, and 6 for the
meloxicam and placebo treatment groups
Lameness at Trot Meloxicam Placebo
Day Grade N % N %
Day 0 None (0) 10 32.3 3 10.3
Minimal (1) 2 6.5 3 10.3
Mild (2) 3 9.7 5 17.2
Moderate (3) 15 48.4 16 55.2
Serious (4) 1 3.2 2 6.9
Severe (5) 0 0.0 0 0.0
Day 3 None (0) 8 25.8 4 13.8
Minimal (1) 3 9.7 2 6.9
Mild (2) 8 25.8 4 13.8
Moderate (3) 9 29.0 15 51.7
Serious (4) 3 9.7 3 10.3
Severe (5) 0 0.0 1 3.5
Day 6 None (0) 12 38.7 4 13.8
Minimal (1) 11 35.5 11 37.9
Mild (2) 5 16.1 2 6.9
Moderate (3) 3 9.7 10 34.5
Serious (4) 0 0.0 2 6.9
Severe (5) 0 0.0 0 0.0
Total 31 100.0 29 100.0for the meloxicam group. Even with baseline adjust-
ment, the meloxicam-treated animals had significantly
less severe lameness on Day 6 (p = 0.040, Table 3).
Application of the same statistical analyses to the data
on the more clinically relevant lameness scale CRLAT
yielded essentially similar results, however the treat-
ment effect on Day 3 was now very close to being sig-
nificant (p = 0.053, Table 3).
LAMEW scores were very low prior to, on the day
after surgery, and throughout the study (Table 4). In fact,
the measurements taken indicated only scores of 0 to 2
(none, minimal, or mild lameness), and the majority of
measurements throughout the study reflected a score of
0, representing no lameness at all at walk. There was no
difference between the placebo and the treatment group
for this measure at any day, and the post-surgical grades
were not significantly higher than the pre-surgical ones.
There was only one animal from the placebo group which
was reported on day 3 only to have a LAMEW score ex-
ceeding 2. The animal otherwise did not show any clinic-
ally relevant sign of pain at rest and therefore rescue
medication was not applied.
The significant treatment effect of meloxicam as seen for
the primary efficacy variable LAMET was also reflected in
secondary endpoints. The treatment groups were signifi-
cantly different in terms of the general assessment of anal-
gesic efficacy at the end of the study (p = 0.029, Figure 1).
Based on combining the categories "Moderate" and "Poor"
to reflect treatment failure and "Excellent" and "Good" to
reflect treatment success, meloxicam treatment was judged
to be successful in 83.9 % of cases, compared to 51.7 % in
placebo-treated animals (p = 0.008). Soft tissue swelling at
the surgical site did not differ between the two treatment
groups on study days 1 and 3 (p = 0.380 and p = 0.292, re-
spectively) but was significantly less in the meloxicam
group on Day 6 (p = 0.010, Figure 2). In particular, the per-
cent of horses categorized as having moderate to severe
swelling of soft tissue at the surgical site on Day 6 was only
9.7 % in the meloxicam group compared to and 34.4 % in
the placebo group.
The treatment group scores for local palpatory pain at
the site of surgery, circumference of the most severely
affected area of the affected limb, and the scores for
wound healing were similar at the various assessment
time points in the study. There was no evidence for any
significant difference between the two treatment groups
with respect to food intake, rectal temperature or heart
Table 3 Summary of the statistical analysis of the primary
parameter lameness at trot (LAMET) and clinically relevant
lameness at trot (CRLAT)
Variables Probability value Variables Probability value
LAMET on Day: CRLAT on Day:
Day 0 0.162 Day 0 0.256
Day 3 0.067 Day 3 0.053
Day 6 0.007 Day 6 0.027
LAMET adjusted for day 0
value at Day:
CLRAT adjusted for day 0
value at Day:
Day 3 0.479 Day 3 0.112
Day 6 0.040 Day 6 0.043
Results of the ordinal logistic regression (OLR) analysis of LAMET and CRLAT
at Days 0, 3, and 6 and at Days 3 and 6, adjusted for the values at Day 0,
based on including Day 0 in the OLR model as a categorical variable. CRLAT
calculation was based on combining AEEP grades 0 and 1 and combining
grades 3 to 5 to generate a 3-point scale.
Figure 1 General assessment of treatment success on Day 6.
Distribution (%) of the categories for the general assessment of
analgesic and anti-inflammatory efficacy of treatment for the
meloxicam and placebo treatment groups on Day 6. Treatment groups
were significantly different based on chi-square analysis (p = 0.029)
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Post-surgery recovery assessments in terms of the num-
ber of attempts which the horses made to stand until
they actually managed to remain standing upright and
the interval between the time of extubation and the time
when the horse was able to remain standing upright
were similar for both groups. No abnormality was ob-
served in the localisation of callus formation in moreTable 4 Distribution of study horses by the AAEP grade for
lameness at walk (LAMEW) on study days 0, 1, 3, and 6 for the
meloxicam and placebo treatment groups
Lameness at Walk Meloxicam Placebo
Day Grade N % N %
Day 0 None (0) 22 71.0 21 72.4
Minimal (1) 1 3.2 4 13.8
Mild (2) 8 25.8 4 13.8
Moderate to severe (3–5)1 0 0.0 0 0.0
Day 1 None (0) 20 64.5 16 55.2
Minimal (1) 2 6.5 6 20.7
Mild (2) 9 29.0 7 24.1
Moderate to severe (3–5)1 0 0.0 0 0.0
Day 3 None (0) 22 71.0 19 65.5
Minimal (1) 7 22.6 6 20.7
Mild (2) 2 6.5 3 10.3
Moderate to severe (3–5)1 0 0.0 1 3.4
Day 6 None (0) 29 93.5 23 79.3
Minimal (1) 2 6.5 4 13.8
Mild (2) 0 0.0 2 6.9
Moderate to severe (3–5)1 0 0.0 0 0.0
Total 31 100.0 29 100.0
1Since all but one horse had LAMEW grades lower than 3, the grades 3–5
were combined.than 80 % of the cases in both treatment groups. No ad-
verse events were observed in any of the horses, and all
were returned to their owners at the end of the study.
Discussion
Good pain control after surgery has been recognized as
important component to prevent negative outcomes in-
cluding poor wound healing and prolonged recovery
[21]. Exacerbations of acute pain can lead to neural
sensitization and release of mediators both peripherally
and centrally, contributing to delayed recovery. This
phenomenon, called wind up, was found to be caused
by N-Methyl D-Aspartate (NMDA) receptor activation
mediated central sensitization, long-term potentiation
of pain (LTP), and transcription-dependent sensitization
[22]. The knowledge of these pathways has led to increased
awareness on post-operative pain and has changed the atti-
tudes towards pain management [22]. Both in human
medicine and in small animal medicine, post-operative in-
tensive pain management is now standard [21,22].
In contrast, the utility of post-operative pain manage-
ment in horses undergoing orthopaedic surgery is still a
matter of controversial discussion, since pain is seen as a
protective mechanism resulting in reduced usage of the
affected limb [4]. The fallacy, however, that pain is pro-
tective and must be allowed to avoid risk for damage after
surgery should be challenged. Post-operative analgesia is
directed at aching pain, whereas sharp pain associated
with inappropriate movements persists [21]. While theor-
etical evidence is strong in support of post-operative pain
management in horses undergoing orthopaedic surgery,
and while post-operative pain management is used at least
in a fraction of horses undergoing castration [23], clinical
proof of improved outcome due to pain management is
limited. In fact, only one placebo-controlled small clinical
Figure 2 Effect on soft tissue swelling. Distribution (%) of the
categories for soft tissue swelling at the surgical site on study days
1, 3, and 6 for the meloxicam and placebo treatment groups.
Treatment groups were not significantly different on study days 1
and 3 (p = 0.380 and p = 0.292, respectively) but were significantly
different on day 6 (p = 0.010) based on chi-square analysis with the
"Moderate" and "Severe" categories combined
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NSAIDs in post-operative pain management [11]. In that
study in horses undergoing arthroscopic surgery, phenyl-
butazone was found to reduce the pain severity if assessed
using a composite pain score, but due to the low number
of cases involved (15 on phenylbutazone and 10 on
placebo), the study failed to demonstrate statistically sig-
nificant and clinically meaningful effects. That study also
demonstrated the difficulties associated with pain assess-
ment in horses after surgery, which is especially challen-
ging when multiple investigators are involved, resulting in
inter-rater variability [24-26].Therefore, the current study was designed to reduce
variability where possible. The surgical condition selected,
i.e. unilateral closed splint bone fracture with marked exo-
stosis and development of connective tissue induration, is
a condition found in sufficient frequency to recruit a siz-
able clinical study in a multi-centre setting. At the same
time, the condition is relatively homogenous, and the
surgical procedure involved is well defined and limited in
extent, thereby reducing the variability within the trial
population. Since no weight bearing structures are directly
involved, horses can be expected not to suffer from un-
acceptable postoperative pain during rest, enabling the use
of placebo. In fact, while the short-acting morphine de-
rivative butorphanol was allowed as rescue medication, no
case required its use. Instead of attempting to quantify
pain, we selected lameness as the primary outcome in that
it reflects the pain perception of the affected horse. Lame-
ness quantification using the AAEP scale is a routine pro-
cedure well established at all participating study sites. Two
different conditions were evaluated. LAMET was selected
to represent the pain perception arising from tissue move-
ments in the surgical region induced by forcing the horses
to trot. LAMEW was selected to represent the pain per-
ception during rest and walking, and this measure was se-
lected to best reflect the overall suffering level during the
recovery. As can be expected from the medical condition,
LAMEW was very low throughout the study and did not
differ between the placebo and the treatment group, indi-
cating that placebo animals were not exposed to unaccept-
able pain (Table 4).
We selected meloxicam as the trial drug because it is
licensed for use in horses for the alleviation of inflamma-
tion and relief of pain in both acute and chronic musculo-
skeletal disorders, as well as for the relief of pain associated
with colic [13]. Information on pharmacokinetic and phar-
macodynamic relationship in orthopaedic conditions, as
well as safety of single and multiple doses, is available
enabling the selection of the dose and dosing interval
[15,27,28]. While phenylbutazone is frequently used in
horses, its use is associated with the highest rate of ad-
verse events of NSAIDs, with a stronger effect on gastric
mucosa as compared to meloxicam, and, therefore, was
not considered as study medication [29,30].
Using this study design, we were able to demonstrate
that preoperative and post-operative administration of
meloxicam resulted in a significant reduction in lameness
on the 6th day after surgery, indicating that the recovery in
animals receiving pain treatment was accelerated com-
pared to placebo-treated animals. This positive effect was
also reflected by the significantly improved overall clinical
assessment of treatment success, reflecting both a signifi-
cant better analgesia and a significant reduction in soft tis-
sue swelling on day 6. The reduced lameness on day 6 is
clinically relevant, since it reduces the risk for development
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render prior surgery needless and that often leads to the
demise of the affected horse [5].
The strongest clinical effects were seen on day 6 after
surgery, while immediately after surgery there was no
difference as assessed by number of attempts to stand
until managing to remain standing and time from extu-
bation to time to remaining to stand upright. This indi-
cates that early recovery from surgery may rather be
related to anaesthetic procedures, which did not differ
between groups, than to post-operative pain control. In
fact, the pain related to the selected surgical procedure
can be expected to be rather limited, having little effect
on time to recovery from anaesthesia. Our data indicate
that, in conditions with limited surgical intervention, early
recovery cannot be improved with post-operative pain
management. On day 3 after surgery, there was a trend, al-
though not statistically significant, towards reduced lame-
ness (Table 3). The reduced efficacy on day 3 compared to
day 6 was somewhat unexpected. One reason for the de-
layed manifestation of clinical benefit may be the selected
treatment scheme. The analgesia of an intravenous dose
of 0.5-1 mg/kg meloxicam lasts in horses up to 24 hours,
supporting once daily dosing [15]. In our study, an intra-
venous dose of 0.6 mg/kg was given immediately prior to
pre-medication of anaesthesia, and the first post-surgical
oral dose was administered about 24 hours later in the
morning on the day following the surgery. An analgesia
gap due to switching from intravenous to oral dosing
could be a potential concern for inappropriate post-
surgical pain relief [4,27]. In future studies, a more
aggressive early treatment, potentially involving a 2nd
intravenous dose, timed to bridge the gap until oral
treatment reaches effective plasma levels, may result in
even further improved outcome.
Our primary endpoint was based on lameness assess-
ment using the 6-point AAEP scale for lameness at trot.
Unfortunately, lameness evaluation is afflicted with low
reproducibility, especially if low grades of lameness are
involved, even if experienced raters are involved [18].
When the mean lameness AAEP score was lower than 1.5,
the inter-rater agreement whether a respective limb was
lame or not was only 61.9 %, while it was 93.1 % if the
lameness score was >1.5 [18]. In view of this problem, we
evaluated whether a reduction of the number of lameness
scores could increase the sensitivity of this scale to treat-
ment effects. For this purpose, the AAEP scores 0 and 1
were grouped to present the positive outcome of none or
minimal lameness, while the scores 3–5 were grouped as
moderate to severe lameness, leaving score 2 as well
recognizable, but mild lameness. This lameness scale, re-
vised to represent clinically relevant differences, aimed at
reducing the uncertainty of evaluating low grades of lame-
ness and also at avoiding the need for rating differentgrades of moderate to severe lameness. Based on applica-
tion of this scale, the study result obtained was essentially
similar but the difference on day 3 became almost statisti-
cally significant (p-value = 0.053, Table 3). This indicates
that the reduced lameness scale may present a method
which is less affected by inter-rater variability.
In carefully reviewing the data, it became evident that,
despite the blinded randomization of the cases resulting
in equal distribution of cases with regard to race, sex, age,
weight, and lameness duration, there was a slight but sta-
tistically non-significant difference in pre-randomization
lameness grade, with a tendency towards less severe lame-
ness in the meloxicam group. While the study aimed at
evaluating the drug effect on surgical pain, this slight dif-
ference could have influenced the study outcome. There-
fore, the OLR analysis of lameness was repeated for day 3
and 6 with adjustment for day 0 values. This adjustment
was without effect on the overall study outcome on day 6.
During the course of the study, no treatment-related
adverse events were recorded, but this was expected
given that meloxicam was dosed in accordance with the
label and that known NSAID related toxicity, including
gastric ulceration and necrosis, require longer treatment
duration to develop [29,31]. In addition, NSAIDs have not
been found to have a detrimental effect on wound healing
[32]. In fact, we showed in this study that the scores for
wound healing were similar at the various assessment time
points in the study, but the treatment resulted in signifi-
cantly reduced swelling of soft tissue on day 6.Conclusions
We have demonstrated for the first time that pre and
post-operative meloxicam administration has a statisti-
cally significant beneficial effect on recovery in horses
undergoing orthopaedic surgery of limited degree. This
positive effect could be identified and verified in a rela-
tively small placebo-controlled field study population of
60 evaluable horses by selecting a homogenous study
population and utilizing a subjective outcome measure,
i.e. lameness at trot. The utilization of a clinically rele-
vant lameness scale increased the sensitivity of the study
to treatment effects. Our results for the first time support
the empirical conclusion drawn by experienced clinicians
that post-operative pain management using clinically safe
NSAIDs, such as meloxicam, is advantageous in equine
orthopaedic surgery.Endnotes
aMetacam® 20 mg/ml Solution for Injection, Boehringer
Ingelheim Vetmedica GmbH, Ingelheim, Germany.
bMetacam® 15 mg/ml Oral Suspension for Horses,
Boehringer Ingelheim Vetmedica GmbH, Ingelheim,
Germany.
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AAEP: American Association of Equine Practitioners; GCP: Good clinical
practice; CRLAT: Clinically relevant lameness at trot; LAMET: Lameness at trot;
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